Cholera Clinical Trial
Official title:
Phase III, Multicenter, Observer-Blinded, Randomized, Active Controlled Trial to Evaluate Immune Non-Inferiority, Safety and Lot-to-Lot Consistency of OCV-S Compared to Shanchol™ in 1 to 40 Years Old Healthy Nepalese Participants
Verified date | June 2023 |
Source | International Vaccine Institute |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
This study is to evaluate immune non-inferiority, safety and lot-to-lot consistency of OCV-S compared to Shanchol™ in 1 to 40 years old healthy Nepalese participants. The investigators hypothesize that the simplified formulation is able to induce non-inferior immunogenicity compared to licensed OCV, Shanchol™.
Status | Completed |
Enrollment | 2530 |
Est. completion date | March 21, 2023 |
Est. primary completion date | December 22, 2022 |
Accepts healthy volunteers | Accepts Healthy Volunteers |
Gender | All |
Age group | 1 Year to 40 Years |
Eligibility | Inclusion Criteria: - Healthy participants 1 to 40 years of age at enrollment - Participants/Parent(s)/Legally authorized representative (LAR) willing to provide written informed consent to participate study voluntarily - Participants/Parent(s)/LAR who can be followed up during the study period and can comply with the study requirements Exclusion Criteria: - Known history of hypersensitivity reactions to other preventive vaccines - Severe chronic diseases or medical conditions based on the medical judgment of the investigator. In particular, a participant with a) chronic infection such as tuberculosis, or sequel of poliomyelitis, b) known history of immune function disorders, c) chronic use of systemic steroids (>2 mg/kg/day or >20 mg/day prednisone equivalent for periods exceeding 10 days)/cytotoxic drugs/immunosuppressants within past 6 weeks, d) active malignancy with the exception of adequately treated basal cell or squamous cell skin cancer, in situ cervical cancer, adequately treated Stage I cancer from which the participant is currently in complete remission, or any other cancer from which the participant has been disease-free for 5 years, e) Congestive heart failure, f) myocardial infarction within the previous 6 months, g) known HIV-infected patients, h) neurological and/or psychiatric disorder, or i) known history of uncontrolled coagulopathy or blood disorders - Participant who planned to or has received other vaccines from 1 month prior to test vaccination excluding a public health vaccination campaign due to an outbreak - Participant concomitantly enrolled or scheduled to be enrolled in another trial - Receipt of blood or blood-derived products in the past 3 months - Participant who has previously received a cholera vaccine - Any female participant who is lactating, pregnant or planning for pregnancy during study period - Participants planning to move from the study area before the end of study period - Employees or the family members of the OCV-S study sites Temporary Contraindication: Should a participant have one of the conditions/situations listed below, the Investigator will postpone primary or subsequent vaccination until the condition/situation is resolved. - Febrile illness (axillary temperature = 37.5°C) or moderate or severe acute illness/infection on the day of vaccination or planned vaccination, according to Investigator's judgment. - Gastrointestinal symptoms including nausea, vomiting, or decreased appetite within 24 hours prior to study initiation. - Administration of antidiarrheal drugs or antibiotics to treat diarrhea or abdominal pain lasting 2 weeks or longer within 6 months prior to study initiation - Diarrhea occurring up to 1 week within 6 months prior to study initiation. - Lactation: Breastfeeding women will not be enrolled. Should a female participant decide to breastfeed during the vaccination period, she will be excluded from further vaccination, but will be followed for safety until the end of the study - Pregnancy Test is necessary for all married female participants of childbearing age. |
Country | Name | City | State |
---|---|---|---|
Nepal | Nepalgunj medical college | Banke | City- Nepalgunj |
Nepal | Kanti Children's Hospital | Kathmandu | Sukedhara |
Nepal | Dhulikhel Hospital | Kavre | Dhulikhel |
Nepal | B.P.Koirala Institute of Health Sciences | Rautahat | Dharan |
Lead Sponsor | Collaborator |
---|---|
International Vaccine Institute | EuBiologics Co.,Ltd |
Nepal,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Other | The equivalence of immunogenicity in 3 lots as measured by seroconversion rates | Proportion of participants showing seroconversion of vibriocidal titers against Vibrio cholerae O1 Inaba and Ogawa 2 weeks after second dose of 3 lots of OCV-S in adults | 2 weeks after second dose of either OCV-S (i.e., one lot of OCV-S) or Shanchol™ | |
Other | Vibriocidal antibody responses | Seroconversion rate and GMT of vibriocidal antibody responses 2 weeks after first dose for all ages and for each age stratum | 2 weeks after first dose of either OCV-S (i.e., one lot of OCV-S) or Shanchol™ | |
Primary | Immune non-inferiority of OCV-S compared to Shanchol™ (i.e., one lot of OCV-S) as measured by seroconversion rates for all ages | Proportion of participants showing seroconversion of vibriocidal titers against Vibrio cholerae O1 Inaba and O1 Ogawa 2 weeks after second dose of either OCV-S (i.e., one lot of OCV-S) or Shanchol™ for all ages | 2 weeks after second dose of either OCV-S (i.e., one lot of OCV-S) or Shanchol™ | |
Primary | Vaccine Safety profile | Frequency of solicited adverse events within 7 days post vaccination, unsolicited adverse events within 28 days post vaccination, Serious Adverse Events (SAEs) after each dose during the entire study period in all ages and in each age stratum | As in Description | |
Secondary | Immune non-inferiority of OCV-S compared to Shanchol™ (i.e., one lot of OCV-S) as measured by GMT for all ages | Geometric Mean Titer (GMT) of vibriocidal antibodies against Vibrio cholerae O1 Inaba and Ogawa 2 weeks after second dose of either OCV-S (i.e., one lot of OCV-S) or Shanchol™ for all ages | 2 weeks after second dose of either OCV-S (i.e., one lot of OCV-S) or Shanchol™ | |
Secondary | Immune non-inferiority of OCV-S compared to Shanchol™ (i.e., one lot of OCV-S) as measured by seroconversion rate in each age stratum | Proportion of participants showing seroconversion against Vibrio cholerae O1 Inaba and Ogawa 2 weeks after second dose of either OCV-S (i.e., one lot of OCV-S) or Shanchol™ in each age stratum | 2 weeks after second dose of either OCV-S (i.e., one lot of OCV-S) or Shanchol™ | |
Secondary | Immune non-inferiority of OCV-S compared to Shanchol™ (i.e., one lot of OCV-S) as measured by GMT in each age stratum | Geometric Mean Titer of vibriocidal antibodies against Vibrio cholerae O1 Inaba and Ogawa 2 weeks after second dose of either OCV-S (i.e., one lot of OCV-S) or Shanchol™ in each age stratum | 2 weeks after second dose of either OCV-S (i.e., one lot of OCV-S) or Shanchol™ | |
Secondary | The equivalence of immunogenicity in 3 lots as measured by GMT | Geometric Mean Titer of vibriocidal antibodies against Vibrio cholerae O1 Inaba and Ogawa 2 weeks after second dose of 3 lots of OCV-S in adults | 2 weeks after second dose of either OCV-S (i.e., one lot of OCV-S) or Shanchol™ |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT01895855 -
Safety and Efficacy Challenge Study of Live Oral Cholera Vaccine Candidate,PXVX0200, to Prevent Cholera
|
Phase 3 | |
Completed |
NCT01339845 -
Introduction of Cholera Vaccine in Bangladesh
|
N/A | |
Recruiting |
NCT05829772 -
Impact Study of Cholera Vaccination in Endemic Areas - Seroprevalence
|
||
Recruiting |
NCT04326478 -
Single Dose Azithromycin to Prevent Cholera in Children
|
Phase 2 | |
Recruiting |
NCT06104345 -
Immune Response Elicited by Concomitant Administration of Oral Typhoid Fever (Vivotif®) and Cholera (Dukoral®) Vaccines
|
Phase 4 | |
Completed |
NCT02928341 -
Impact Evaluation of Urban Water Supply Improvements on Cholera and Other Diarrhoeal Diseases in Uvira, Democratic Republic of Congo
|
N/A | |
Completed |
NCT02864433 -
Evaluation of a Pilot Program to Introduce Cholera Vaccine in Haiti as Part of Global Cholera Control Efforts
|
||
Recruiting |
NCT06003816 -
Cholera-Hospital-Based-Intervention-for-7-Days (CHoBI7) Water, Sanitation, and Hygiene (WASH) Case Area Targeted Intervention (CATI)
|
N/A | |
Not yet recruiting |
NCT05771779 -
Co-administration Study of OCV, TCV and MR
|
Phase 3 | |
Not yet recruiting |
NCT06455852 -
Correlates of Protection for Cholera
|
N/A | |
Completed |
NCT04150250 -
Cholera Anti-Secretory Treatment Trial
|
Phase 2 | |
Terminated |
NCT00624975 -
Safety and Immunogenicity of Peru-15 Vaccine When Given With Measles Vaccine in Healthy Indian and Bangladeshi Infants
|
Phase 2 | |
Completed |
NCT00226616 -
Zinc Supplementation in Cholera Patients
|
Phase 3 | |
Completed |
NCT03373669 -
Effect of Extended Dose Intervals on the Immune Response to Oral Cholera Vaccine
|
Phase 4 | |
Completed |
NCT02094586 -
A Phase 3 Lot to Lot Consistency Study of Live Oral Cholera Vaccine, PXVX0200 in Healthy Adults
|
Phase 3 | |
Completed |
NCT02100631 -
A Study of Live Oral Cholera Vaccine, PXVX200 in Healthy Older Adults
|
Phase 3 | |
Completed |
NCT01823939 -
PK Study of iOWH032 in Adult Male/Female Healthy Volunteers & Adult Males With Cholera
|
Phase 1 | |
Completed |
NCT01365442 -
Pilot Introduction of Oral Cholera Vaccine in Orissa, India
|
N/A | |
Completed |
NCT00128011 -
Safety and Immunogenicity of a New Formulation of a Bivalent Killed, Whole-Cell Oral Cholera Vaccine
|
Phase 2 | |
Completed |
NCT00672308 -
Efficacy of Benefiber-Added, Reduced-Osmolarity WHO-ORS in the Treatment of Cholera in Adults
|
Phase 2 |